C.Ana Ab Test Kit Canine Anaplasma Antibody Rapid Test

Name: C.Ana Ab Test Kit Canine Anaplasma Antibody Rapid Test
Brand: HangZhou Testsea biotechnology Co., Ltd.
SKU: 1916656181

Zhejiang, ChinaHangZhou Testsea biotechnology Co., Ltd.

US$2.50

200-799 Pieces

US$2.40

800-3,999 Pieces

US$2.20

4,000+ Pieces

Sample price:US$1.00/piece.Request sample

Product profile

Customization

Available

Type

Detection Card

Syringe

Veterinary Rapid Diagnosis Test

Model NO.

109137

Blood Sampling Needle

Veterinary Rapid Diagnosis Test

Breathing Pattern

Veterinary Rapid Diagnosis Test

Animal Anesthesia Machine Control Method

Veterinary Rapid Diagnosis Test

Format

Cassette

Specimen

Serum/Plasma

Sensitivity

97.67%

Specificity

98.3%

OEM/ODM

Available

Box Specification

20 or 10 Tests/Box

Certificate

ISO 13485 & ISO 9001

Quantity Per Carton

800 Tests

Weight/Carton

10.0kg

Shelf Life

24 Months

Test Time

5-10 Minutes

Transport Package

64*36*36.5cm

Specification

155*150*68mm

Trademark

Testsealabs

Origin

China

HS Code

3005109000

Production Capacity

3 000 000 Tests/Day

Company profile

HangZhou Testsea biotechnology Co., Ltd.

Zhejiang, China

CertifiedBusiness Type: Manufacturer/Factory & Trading Company CertifiedR&D Capacity: ODM Service Available & OEM Service AvailableExport Year: 2022-04-08Nearest Port: Shanghai, Ningbo, ShenzhenAverage Response Time: ≤10.15h CertifiedTerms of Payment: LC, T/T, D/P

AI-Powered supplier vetting

SummaryTestsea Biotechnology is identified as a China-based limited company in Hangzhou, with records describing it as both a trading company and manufacturer/factory. Its stated capabilities include in-vitro diagnostic, veterinary, rapid-test, reagent, and medical-machine products. The supplier reports ISO 9001 and GMP certification, more than 10 production lines, 50 R&D engineers, 50 quality-control staff, and exports to multiple global regions. It describes three technical platforms and sales coverage exceeding 100 countries and regions. However, the evidence does not establish after-sales performance, financial credibility, or product-customization capability. One record associates the supplier with a 2025 THC urine-test product and a Vietnamese buyer, but this is limited customer evidence and does not independently verify broader performance.

Supplier typeThe supplier is identified as a limited company headquartered in Hangzhou, China, and is described as both a trading company/manufacturer-factory. A separate record characterizes the company nature as a factory, supporting a manufacturing role alongside trading activity.

CertificationsThe supplier reports ISO 9001 and GMP certification under its management-system certifications. These are explicit certifications relevant to quality and manufacturing controls.

R&D capabilityThe supplier states that it develops core innovative raw-material technologies and has established immunological detection, molecular-biology detection, and protein core-sheet inspection platforms. The reported 50 R&D engineers and continuing R&D investment further support an established innovation function.

Production capacityThe supplier reports more than 10 production lines, 50 quality-control staff, a one-month off-peak lead time, and broad diagnostic-product offerings. It also reports 90% export sales and access to Shanghai, Ningbo, and Shenzhen ports, although the stated peak-season fulfillment time of 6–12 months indicates substantial seasonal capacity constraints.

Client casesThe supplier states that its products have been sold in more than 100 countries and regions. A separate record identifies a THC urine-test product and one associated Vietnamese buyer, but it does not provide verifiable case details such as order scale, duration, performance results, or references.